Through the arduous endeavor of the Fourth Military Medical University and Chengdu Hoist INC., Ltd., the topic of "Research on Iodine ［131 I］Mituximab Injection", a special project of the state S&T project of "Innovative Drug and Modernization of Traditional Chinese Medicine" achieved significant technical breakthrough and obtained the new drug certificate from the State Food and Drug Administration on April 20, 2005. The product is about to appear on the market.

This drug is characterized mainly by definite mechanism of action (having the targeted effect of being directed at the part of liver cancer and the effect of sealing the target antigen), clear anti-body gene and target molecule and advanced production technology. This drug owns 4 state invention patents, 3 PCT international patents that are on the stage of substantive examination in the US, Europe and Japan. This is the first mab drug in the world used for treating primary liver cancer and also the first tumor targeted anti-body drug in China with independent intellectual property rights. The successful development of this drug is of far-reaching importance to the development of the anti-body drug industry with Chinese characteristics.